ZHEJIANG WOLWO BIO-PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 22.74 CNY | +2.90% |
|
-1.77% | -21.59% |
| Sales 2024 * | 1.08B 149M | Sales 2025 * | 1.31B 180M | Capitalization | 11.91B 1.64B |
|---|---|---|---|---|---|
| Net income 2024 * | 415M 57.27M | Net income 2025 * | 507M 69.97M | EV / Sales 2024 * | 11 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 9.12 x |
| P/E ratio 2024 * |
28.7
x | P/E ratio 2025 * |
23.4
x | Employees | 1,709 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 49.91% |
More Fundamentals
* Assessed data
More news
| 1 day | +2.90% | ||
| 1 week | -1.77% | ||
| Current month | +0.04% | ||
| 1 month | -5.60% | ||
| 3 months | -1.13% | ||
| 6 months | -16.89% | ||
| Current year | -21.59% |
1 week
22.00
23.48
1 month
21.9824.44
Current year
18.4429.10
1 year
18.4447.72
3 years
18.4476.36
5 years
18.4497.90
10 years
6.5797.90
| Managers | Title | Age | Since |
|---|---|---|---|
Geng Xi Hu
CEO | Chief Executive Officer | 60 | 02-09-18 |
Guo Qi Wang
DFI | Director of Finance/CFO | 50 | 16-04-05 |
Tao Jin
CHM | Chairman | 38 | 12-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Geng Xi Hu
CEO | Chief Executive Officer | 60 | 02-09-18 |
Ni Chen Yan
BRD | Director/Board Member | 59 | 11-01-27 |
Lu Zhang
BRD | Director/Board Member | 45 | 11-01-27 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.50% | 2 M€ | -20.02% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-22 | 22.74 | +2.90% | 6,427,262 |
| 24-04-19 | 22.1 | -3.03% | 4,692,111 |
| 24-04-18 | 22.79 | +0.84% | 3,852,900 |
| 24-04-17 | 22.6 | +1.07% | 4,057,105 |
| 24-04-16 | 22.36 | -3.41% | 5,570,896 |
End-of-day quote Shenzhen S.E., April 21, 2024
More quotes
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. is a China-based company principally engaged in the research, development, production and sale of bio-pharmaceutical products. The Company's main products include Dermatophagoides Farinae Drops and Dermatophagoides Farinae Skin Prick Diagnostic Kits. The Company's products are primarily used for the treatment of allergic rhinitis caused by dust mite allergy, the desensitization of allergic asthma and the in-vivo diagnosis of dust mite drops. The Company distributes its products in domestic market.
Sector
Pharmaceuticals
Calendar
2024-05-17
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
22.74
CNY
Average target price
29
CNY
Spread / Average Target
+27.53%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -21.59% | 1.64B | |
| +25.46% | 659B | |
| +26.27% | 557B | |
| -4.86% | 359B | |
| +16.44% | 322B | |
| +8.34% | 297B | |
| +6.58% | 215B | |
| +7.54% | 210B | |
| -6.22% | 200B | |
| -8.79% | 149B |
- Stock Market
- Equities
- 300357 Stock
